Published in J Am Soc Mass Spectrom on July 02, 2013
Dopamine-induced α-synuclein oligomers show self- and cross-propagation properties. Protein Sci (2014) 0.85
The N-terminal residues 43 to 60 form the interface for dopamine mediated α-synuclein dimerisation. PLoS One (2015) 0.80
Mini review: linkage between α-Synuclein protein and cognition. Transl Neurodegener (2015) 0.77
Digested disorder: Quarterly intrinsic disorder digest (July-August-September, 2013). Intrinsically Disord Proteins (2014) 0.76
Cis→Trans Isomerization of Pro(7) in Oxytocin Regulates Zn(2+) Binding. J Am Soc Mass Spectrom (2016) 0.75
Electrospray ionization for mass spectrometry of large biomolecules. Science (1989) 16.50
Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science (2001) 4.48
Amyloid formation by globular proteins under native conditions. Nat Chem Biol (2009) 3.72
Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem (2001) 3.60
Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Soc (2005) 3.13
Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem (2001) 3.13
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem (2001) 1.99
Deciphering drift time measurements from travelling wave ion mobility spectrometry-mass spectrometry studies. Eur J Mass Spectrom (Chichester, Eng) (2009) 1.84
Top-down ESI-ECD-FT-ICR mass spectrometry localizes noncovalent protein-ligand binding sites. J Am Chem Soc (2006) 1.68
Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci (2009) 1.66
Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci (2004) 1.63
Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J (2005) 1.51
Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem (2005) 1.47
Α-synuclein misfolding and Parkinson's disease. Biochim Biophys Acta (2011) 1.43
Estimates of protein surface areas in solution by electrospray ionization mass spectrometry. Anal Chem (2005) 1.42
NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J (2004) 1.41
Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A (2012) 1.40
Characterizing the resolution and accuracy of a second-generation traveling-wave ion mobility separator for biomolecular ions. Analyst (2011) 1.37
How useful is ion mobility mass spectrometry for structural biology? The relationship between protein crystal structures and their collision cross sections in the gas phase. Analyst (2010) 1.32
Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem (2001) 1.29
Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc (2006) 1.28
Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. Neurotoxicology (2002) 1.25
Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res (2010) 1.24
Cellular polyamines promote the aggregation of alpha-synuclein. J Biol Chem (2002) 1.21
Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein. Biochemistry (2008) 1.18
Alpha-synuclein: stable compact and extended monomeric structures and pH dependence of dimer formation. J Am Soc Mass Spectrom (2004) 1.17
Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation. J Am Chem Soc (2008) 1.15
Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. Exp Mol Med (2011) 1.12
Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav Immun (2012) 1.11
Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism. Neuroimmunomodulation (2001) 1.10
Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation. Free Radic Biol Med (2009) 1.09
The structure of dopamine induced alpha-synuclein oligomers. Eur Biophys J (2010) 1.08
Characterization of intrinsically disordered proteins with electrospray ionization mass spectrometry: conformational heterogeneity of alpha-synuclein. Proteins (2010) 1.05
Copper(II) binding to alpha-synuclein, the Parkinson's protein. J Am Chem Soc (2008) 1.05
Modulation of alpha-synuclein aggregation by dopamine: a review. Neurochem Res (2009) 1.02
Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J (2005) 0.98
Cu2+ binding modes of recombinant alpha-synuclein--insights from EPR spectroscopy. J Am Chem Soc (2008) 0.97
Decreased reuptake of dopamine in the dorsal striatum in the absence of α-synuclein. Brain Res (2011) 0.95
Advances in ion mobility spectrometry-mass spectrometry reveal key insights into amyloid assembly. Biochim Biophys Acta (2012) 0.94
Oligomeric alpha-synuclein and its role in neuronal death. IUBMB Life (2010) 0.94
Spermine binding to Parkinson's protein alpha-synuclein and its disease-related A30P and A53T mutants. J Phys Chem B (2008) 0.93
Dopamine-induced conformational changes in alpha-synuclein. PLoS One (2009) 0.93
Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease. Chem Biol Interact (2011) 0.93
Interactions between metals and alpha-synuclein--function or artefact? FEBS J (2007) 0.92
Compact conformations of α-synuclein induced by alcohols and copper. Proteins (2011) 0.89
Interaction between α-synuclein and other proteins in neurodegenerative disorders. ScientificWorldJournal (2011) 0.89
Bioinorganic chemistry of Parkinson's disease: structural determinants for the copper-mediated amyloid formation of alpha-synuclein. Inorg Chem (2010) 0.89
Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study. Neurosci Lett (2007) 0.81
Oxidative stress effect of dopamine on α-synuclein: electroanalysis of solvent interactions. ACS Chem Neurosci (2012) 0.77
Crystal structure of monomeric human beta-2-microglobulin reveals clues to its amyloidogenic properties. Proc Natl Acad Sci U S A (2002) 1.66
In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci (2007) 1.52
Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J (2005) 1.51
Sun exposure may increase risk of prostate cancer in the high UV environment of New South Wales, Australia: a case-control study. Int J Cancer (2012) 1.48
Hierarchical assembly of beta2-microglobulin amyloid in vitro revealed by atomic force microscopy. J Mol Biol (2003) 1.39
Remoteness of residence and survival from cancer in New South Wales. Med J Aust (2004) 1.33
Using linked routinely collected health data to describe prostate cancer treatment in New South Wales, Australia: a validation study. BMC Health Serv Res (2011) 1.19
Stacked sets of parallel, in-register beta-strands of beta2-microglobulin in amyloid fibrils revealed by site-directed spin labeling and chemical labeling. J Biol Chem (2010) 1.17
Evidence-based uncertainty: recent trial results on prostate-specific antigen testing and prostate cancer mortality. Med J Aust (2009) 1.09
Cancer screening among migrants in an Australian cohort; cross-sectional analyses from the 45 and Up Study. BMC Public Health (2009) 1.03
Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide. Biophys J (2007) 0.98
Risk factors for erectile dysfunction in a cohort of 108 477 Australian men. Med J Aust (2013) 0.95
Parental pregnancy intention and early childhood stunting: findings from Bolivia. Int J Epidemiol (2004) 0.93
Role of the N and C-terminal strands of beta 2-microglobulin in amyloid formation at neutral pH. J Mol Biol (2003) 0.93
Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease. Proc Natl Acad Sci U S A (2008) 0.93
Dimeric structures of alpha-synuclein bind preferentially to lipid membranes. Biochim Biophys Acta (2008) 0.92
Clinicians' attitudes to prostate cancer peer-support groups. BJU Int (2006) 0.91
Linker histone H1 binds to disease associated amyloid-like fibrils. J Mol Biol (2006) 0.90
Estimating regional variation in cancer survival: a tool for improving cancer care. Cancer Causes Control (2004) 0.90
Patterns of surgical care for prostate cancer in NSW, 1993-2002: rural/urban and socio-economic variation. Aust N Z J Public Health (2008) 0.89
Cancer incidence and mortality in people aged less than 75 years: changes in Australia over the period 1987-2007. Cancer Epidemiol (2013) 0.87
Characteristics of cases with unknown stage prostate cancer in a population-based cancer registry. Cancer Epidemiol (2013) 0.87
Projecting prevalence by stage of care for prostate cancer and estimating future health service needs: protocol for a modelling study. BMJ Open (2011) 0.86
Psychometric properties of the DSM scale for depression (DSD) with Korean-American youths. Issues Ment Health Nurs (2002) 0.84
Sociodemographic and health-related predictors of self-reported mammogram, faecal occult blood test and prostate specific antigen test use in a large Australian study. BMC Public Health (2013) 0.84
Prostate-specific antigen levels in men aged 70 years and over: findings from the CHAMP study. Med J Aust (2012) 0.83
Prostate cancer mortality outcomes and patterns of primary treatment for Aboriginal men in New South Wales, Australia. BJU Int (2015) 0.83
The impact of pregnancy intention on breastfeeding duration in Bolivia and Paraguay. Stud Fam Plann (2007) 0.83
Study of receptor-chaperone interactions using the optical technique of spectroscopic ellipsometry. Biophys J (2011) 0.82
Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. Br J Clin Pharmacol (2014) 0.82
A comprehensive evaluation of bladder cancer epidemiology and outcomes in Australia. Int Urol Nephrol (2014) 0.80
A randomised controlled trial of the Flinders Program™ of chronic condition management in Vietnam veterans with co-morbid alcohol misuse, and psychiatric and medical conditions. Aust N Z J Psychiatry (2013) 0.80
Quantification of ligand binding to G-protein coupled receptors on cell membranes by ellipsometry. PLoS One (2012) 0.80
Compromised periodontal status in an urban Sri Lankan population with type 2 diabetes. J Clin Periodontol (2010) 0.80
Recombinant " IMS TAG" proteins--a new method for validating bottom-up matrix-assisted laser desorption/ionisation ion mobility separation mass spectrometry imaging. Rapid Commun Mass Spectrom (2013) 0.80
Skin cancer in general practice --impact of an early detection campaign. Aust Fam Physician (2007) 0.79
Impact of Australian celebrity diagnoses on prostate cancer screening. Med J Aust (2009) 0.79
Clinician-led improvement in cancer care (CLICC)--testing a multifaceted implementation strategy to increase evidence-based prostate cancer care: phased randomised controlled trial--study protocol. Implement Sci (2014) 0.79
The association of ultraviolet radiation-B (305 nm), season of diagnosis, and latitude on the survival outcome of prostate cancer in the high UV environment of Australia. Cancer Causes Control (2013) 0.78
Analysis of protein interactions at native chloroplast membranes by ellipsometry. PLoS One (2012) 0.78
A randomised controlled trial of a mindfulness intervention for men with advanced prostate cancer. BMC Cancer (2013) 0.77
Laparoscopic simulation for all: two affordable, upgradable, and easy-to-build laparoscopic trainers. J Surg Educ (2013) 0.76
The ban on phenacetin is associated with changes in the incidence trends of upper-urinary tract cancers in Australia. Aust N Z J Public Health (2014) 0.75
A return to the Asclepeia: a physician's enduring obligation to his or her patients. J Miss State Med Assoc (2014) 0.75
The relationship between solar UV exposure, serum vitamin D levels and serum prostate-specific antigen levels, in men from New South Wales, Australia: the CHAMP study. World J Urol (2013) 0.75
Analysis of Abeta interactions using ProteinChip technology. Methods Mol Biol (2008) 0.75
Geographic disparities in prostate cancer outcomes--review of international patterns. Asian Pac J Cancer Prev (2015) 0.75